Previous Article | Next Article 
Journal of Virology, December 1999, p. 10029-10039, Vol. 73, No. 12
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
An Epitope of the Semliki Forest Virus Fusion
Protein Exposed during Virus-Membrane Fusion
Anna
Ahn,
Matthew R.
Klimjack,
Prodyot K.
Chatterjee, and
Margaret
Kielian*
Department of Cell Biology, Albert Einstein
College of Medicine, Bronx, New York 10461
Received 29 January 1999/Accepted 7 September 1999
 |
ABSTRACT |
Semliki Forest virus (SFV) is an enveloped alphavirus that infects
cells via a membrane fusion reaction triggered by acidic pH in the
endocytic pathway. Fusion is mediated by the spike protein E1 subunit,
an integral membrane protein that contains the viral fusion peptide and
forms a stable homotrimer during fusion. We have characterized four
monoclonal antibodies (MAbs) specific for the acid conformation of E1.
These MAbs did not inhibit fusion, suggesting that they bind to an E1
region different from the fusion peptide. Competition analyses
demonstrated that all four MAbs bound to spatially related sites on
acid-treated virions or isolated spike proteins. To map the binding
site, we selected for virus mutants resistant to one of the MAbs,
E1a-1. One virus isolate, SFV 4-2, showed reduced binding of three
acid-specific MAbs including E1a-1, while its binding of one
acid-specific MAb as well as non-acid-specific MAbs to E1 and E2 was
unchanged. The SFV 4-2 mutant was fully infectious, formed the E1
homotrimer, and had the wild-type pH dependence of infection. Sequence
analysis demonstrated that the relevant mutation in SFV 4-2 was a
change of E1 glycine 157 to arginine (G157R). Decreased binding of MAb
E1a-1 was observed under a wide range of assay conditions, strongly
suggesting that the E1 G157R mutation directly affects the MAb binding
site. These data thus localize an E1 region that is normally hidden in
the neutral pH structure and becomes exposed as part of the
reorganization of the spike protein to its fusion-active conformation.
 |
INTRODUCTION |
All enveloped animal viruses use
membrane fusion to cross the barrier of the host cell membrane and
deliver the virus genome into the cytoplasm. This critical membrane
fusion reaction is mediated by the virus spike protein, which undergoes
structural rearrangements that convert the protein into a fusion-active
form. The general scheme of the structural rearrangements, although differing mechanistically for different groups of viruses, appears to
involve the release of a hydrophobic fusion peptide from a previously
hidden or inactive position within the spike protein and its insertion
into the target membrane to trigger fusion. A key question is the
mechanism of protein refolding from a fusion-inactive form to the
fusion-active form that carries out fusion peptide insertion. Molecular
understanding of this refolding reaction may lead to the development of
novel strategies to block virus fusion and infection. For a group of
diverse viruses exemplified by influenza virus, the fusogenic spike
protein conformational change involves the formation of an extended
-helical coiled-coil domain that appears to be a key feature of the
fusion mechanism (17, 36).
The alphavirus Semliki Forest virus (SFV) is a small, highly organized
enveloped RNA virus whose fusion activity has been extensively studied
(20, 21, 40). The SFV fusion reaction is triggered by low pH
(<pH 6.2) during the endocytic uptake of the virus by cells. Fusion
and infection are blocked by weak bases such as NH4Cl or
specific inhibitors such as bafilomycin, which act to raise the pH
within endocytic vesicles (14, 20). The SFV spike promoter
is composed of the E1 and E2 transmembrane subunits, each ~50 kDa and
associated as a noncovalent heterodimer, and the E3 subunit, a
peripheral polypeptide of ~10 kDa. Each virus particle contains 240 copies of this spike promoter organized as 80 trimeric spikes,
[E1-E2-E3]3. Fusion is mediated by the spike E1 subunit,
which binds to target membranes and contains a highly conserved
hydrophobic domain from amino acids 79 to 97 that is believed to be the
fusion peptide (12, 20, 24, 26).
Studies of the SFV spike protein during fusion indicate that upon
exposure to mildly acidic pH, the E1-E2 dimer dissociates. E1 then
undergoes conformational changes that result in the exposure of
previously masked epitopes for monoclonal antibody (MAb) binding and
the formation of a highly stable, trypsin-resistant E1 homotrimer (20, 24). These E1 conformational changes occur with
kinetics slightly faster than those of fusion (3, 19) and
are enhanced by the presence of target membranes containing cholesterol
and sphingolipid, two lipid components that are specifically required for SFV fusion (20, 21, 26, 49). E1 then associates with the
target membrane by insertion of the fusion peptide, and membrane fusion
is triggered.
Central questions in understanding SFV fusion include the mechanism of
formation of the critical E1 homotrimer and the identities of the
regions of the E1 protein that are involved in its fusogenic refolding.
Structural predictions suggest that, unlike spike proteins of the
influenza virus class, SFV E1 does not refold into an extended
-helical coiled coil during fusion (26). Thus, the
formation of the fusion-active E1 trimer may represent a novel
refolding mechanism. One tool in identifying regions of viral spike
proteins that become exposed during fusion has been to localize the
binding sites for MAbs that are specific for the fusion-active
conformation of the spike (48). The fusion-active,
low-pH-treated form of SFV E1 is specifically recognized by four MAbs
that inefficiently recognize the pH 7 form of E1 (23, 45).
Three of these MAbs were isolated and characterized by our laboratory
(23) and are termed E1a-1, E1a-2, and E1a-3. The fourth MAb,
anti-E1", was originally isolated by Boere et al. (1) and
further characterized by Wahlberg and coworkers (3, 44, 45).
Extensive evidence indicates that exposure of the epitopes recognized
by these acid-specific MAbs is relevant to the fusion activity of SFV.
First, the epitopes are exposed with the same pH and temperature
dependence as are required for virus fusion (3, 19, 23).
Detailed kinetic studies demonstrate that epitope exposure occurs
slightly faster than fusion (3, 19). This is in contrast to
other SFV MAbs that detect spike epitopes exposed after the fusion
reaction is completed (19). SFV fusion is remarkably
dependent on cholesterol and sphingolipid as well as low pH, and the
conformational changes detected by the antibodies are strikingly
dependent on both lipids when either the virus (4, 6) or the
spike ectodomain (26) is assayed. The epitopes become
exposed during the endocytic entry of the virus into the cell and, like
fusion, epitope exposure is blocked by agents such as NH4Cl
or monensin that interfere with endosome acidification (23, 28,
32, 38, 45). Several virus E2 mutants that shift the pH
dependence of virus fusion by shifting the pH dependence of E1-E2 dimer
dissociation also shift the pH dependence of epitope exposure (13,
33). A number of biochemical experiments demonstrate that the
epitopes are not simply exposed as part of a general "loosening" of
the tightly packed virus structure at low pH, since detergent
solubilization, for example, did not make the epitopes accessible
(23). Lastly, the same pool of E1 protein reacts with the
antibodies, binds specifically to cholesterol- and
sphingolipid-containing target liposomes, and forms the homotrimeric
structure believed to be critical for the fusion reaction
(26). Thus, the kinetics and properties of epitope exposure
argue for the relevance of these conformational changes to fusion.
We set out to determine the functional effects of E1 binding by these
four MAbs, to characterize the similarities and differences in their
binding site(s), and in particular to localize the epitope(s) with
which they interact. Our studies showed that the presence of the MAbs
did not affect fusion and that all four MAbs bound to a spatially
related site(s) on E1. The region of the spike protein recognized by
three of the MAbs appears distinct from the fusion peptide and from the
epitope recognized by anti-E1". Our results thus indicate a region of
E1 other than the virus fusion peptide that becomes exposed during the
SFV fusion reaction at acidic pH.
 |
MATERIALS AND METHODS |
Viruses and antibodies.
The wild-type (wt) virus used in
these studies was a well-characterized plaque-purified stock virus
(13, 42), and the SFV fus-1 mutant was previously
isolated and characterized as a pH shift fusion mutant (13,
25). All virus stocks were prepared by propagation in BHK cells
at low multiplicity in minimal essential medium plus 0.2% bovine serum
albumin (BSA) and 10 mM HEPES (pH 7.4) and stored at
70°C
(25).
[35S]methionine-[35S]cysteine-labeled virus
was prepared in BHK cells, purified by banding on a discontinuous
sucrose gradient (25), and stored at
70°C in ~45%
(wt/wt) sucrose in TN buffer (50 mM Tris [pH 7.4], 100 mM NaCl).
Unlabeled virus was prepared in BHK cells, purified on tartrate
gradients, and stored at
70°C in TN buffer (25).
The E1 acid conformation-specific MAbs E1a-1, E1a-2, and E1a-3 and the
non-acid-specific E1 and E2 MAbs E1-1 and E2-1 were previously isolated
and characterized in our laboratory (23), and were prepared
in large quantities for biotinylation and other experiments by growth
in a CELLMAX (Gibco BRL, Gaithersburg, Md.) in the Einstein Hybridoma
facility. MAb anti-E1" was obtained as a concentrated ascites
preparation from Harm Snippe and has been previously characterized for
its reactivity to the low-pH conformation of E1 (26, 45).
Biotin conjugation was performed with sulfo-NHS-biotin (Pierce,
Rockford, Ill.).
Functional effects of antibodies on virus fusion.
Liposome
binding studies measured the cofloatation of radiolabeled SFV with
liposomes on sucrose gradients as previously described (24),
with pH treatment performed in the presence of the indicated concentrations of antibodies. Virus-liposome fusion was assayed by
monitoring the decrease in the eximer peak of pyrene-labeled SFV upon
fusion with unlabeled liposomes prepared by extrusion (7,
24). Pyrene-labeled wt SFV was prepared by propagation in one
roller bottle of BHK cells in which the phospholipids were prelabeled
by growth in the presence of 10 µg of pyrene (Molecular Probes,
Eugene, Oreg.) per ml (3, 44). Labeled virus was purified by
banding on a discontinuous sucrose gradient (25). Fusion
assays were performed with pyrene-labeled virus at concentrations of
0.6 µM virus lipid, liposomes at concentrations of 200 µM lipid, and the indicated concentrations of antibodies; HNE buffer (5 mM HEPES
[pH 7.0], 150 mM NaCl, 0.1 mM EDTA) was used at 37°C in a stirred
cuvette with a Perkin-Elmer LS5 fluorometer (3, 44). Fusion
was triggered by the addition of a pretitrated volume of 0.3 M
morpholinoethanesulfonic acid (MES) (pH 4.8), to give a final pH of
5.5.
Fusion of virus with the plasma membrane of BHK cells was assayed
essentially as previously described (
42,
45). In brief,
virus was bound on ice to BHK cells grown on 12-mm coverslips,
and the
coverslips were then inverted over a 75-µl drop of medium
(RPMI
without bicarbonate plus 0.2% BSA and 30 mM sodium succinate
[pH
5.5]) containing the indicated antibody on a square of Parafilm
and
incubated at the indicated temperature for the indicated time
(1 to 5 min). The coverslips were flooded with medium to neutralize
and
reinverted, and the cells were incubated overnight at 28°C
in minimal
essential medium containing 0.2% BSA and 10 mM HEPES
(pH 7.4), plus 20 mM NH
4Cl to prevent secondary infection. Infected
cells
were quantitated by immunofluorescence with a polyclonal
antibody to
the SFV spike protein (
42).
Selection of antibody binding mutants.
The overall strategy
was to pH treat the virus to expose the binding site for MAb E1a-1,
remove MAb-reactive virus by immunoprecipitation, and repeat for
multiple selections. This strategy is similar to that successfully used
to isolate a Sindbis virus MAb-resistant mutant (30). A
150-µl volume of wt virus stock containing ~109 PFU was
adjusted to a final pH of ~5.5 by dilution with an equal volume of
buffer containing 50 mM succinate (pH 5.0) and 100 mM NaCl, incubated
for 5 min on ice, and neutralized by the addition of a precalibrated
volume of 0.5 N NaOH. This mild pH treatment did not reduce virus
infectivity (3) and induced full reactivity with MAb E1a-1
as tested by enzyme-linked immunosorbent assay (ELISA) of whole virus
(data not shown). The virus was then incubated overnight on ice with 3 µg of biotin-conjugated MAb E1a-1. Antibody-virus complexes were
removed by gentle rotation for 1 h at 4°C with 100 µl of
streptavidin-conjugated magnetic particles (PerSeptive Diagnostics,
Inc., Cambridge, Mass.), and bound virus and particles were
precipitated with a magnet-containing test tube rack (Dynal, Inc., Lake
Success, N.Y.). The specific selection gave a ~10-fold reduction in
viral titer, and no reduction resulted when an unrelated biotin-conjugated MAb was substituted. Virus remaining in the supernatant was expanded by growth on four independent plates of BHK
cells at a multiplicity of ~1 PFU/cell for 6 to 7 h. The selection of these individual stocks was repeated for a total of nine
cycles each, a point at which further selection gave little reduction
in the titer of the virus stocks. The selected stocks were plaqued
under agarose, and isolated plaques were picked and expanded by growth
on BHK cells in 24-well trays until the cells displayed cytopathic
effects. Virus isolates were treated at low pH with succinate buffer as
above, and screened by the ELISA described below for reactivity with
MAbs E2-1 and E1a-1. Isolates showing strong reactivity with the E2
MAb, indicating a high titer of virus, and reduced activity with the
selecting MAb were expanded and further tested as described below.
Other selections based on neutralization with acid
conformation-specific MAb, second antibody, and complement or based on
epitope exposure by heat treatment did not produce sufficient specific
selection pressure and were not further pursued (data not shown).
ELISA analysis.
Antibody competition experiments with intact
virus were performed by coating ELISA wells with 1 µg of MAb E2-1 per
ml; this MAb was previously shown to bind to intact virus after either acidic or neutral pH treatment (23). The plates were blocked with 1% BSA, purified acidic- or neutral-pH-treated virus was added at
a protein concentration of 3 µg/ml, and the mixture incubated overnight at 4°C. The tethered virus was then reacted for 1 to 2 h at 37°C with 60 to 100 ng of biotin-conjugated MAb E1a-1 or anti-E1" per ml, concentrations that were shown to be in the linear range of the assay, in the presence of the indicated concentrations of
unlabeled competing MAb. The plate was developed by incubation with
saturating concentrations of streptavidin-alkaline phosphatase (Fisher
Scientific, Pittsburgh, Pa.) for 1.5 h at 37°C followed by
substrate incubation. Antibody competition experiments with purified
detergent-solubilized spike proteins were performed by directly coating
ELISA wells with 0.5 µg of spike proteins per ml for 1 to 2 h at
37°C, blocking with BSA, and then incubating with biotin-MAb and
competitors as above. Spike proteins were purified by Triton X-114
phase separation (2) of gradient-banded wt and mutant viruses.
To screen for mutants with reduced binding of MAb E1a-1, virus stocks
were treated at pH 5.5 for 3 min at 37°C with succinate
buffer as
above, neutralized, and adjusted to 0.5% Triton X-100
to disrupt the
virus. Samples were incubated overnight at 4°C
in ELISA wells that
had been precoated with 1 µg of either MAb
E2-1 or MAb E1a-1 per ml.
Bound spike proteins were detected with
a rabbit antibody to the spike
protein followed by goat anti-rabbit
immunoglobulin G conjugated with
alkaline phosphatase (Sigma,
St. Louis, Mo.). This assay could reliably
detect pH-dependent
epitope exposure in virus stocks with titers as low
as 2 × 10
7 PFU/ml.
Virus sequence analysis.
RNA was prepared from virus grown
at low multiplicity in one 75-cm2 flask of BHK cells
(13). The sequence of the RNA encoding the structural
proteins was determined by reverse-transcription (RT)-PCR amplification
with Pfu polymerase (Stratagene, La Jolla, Calif.) and
automated sequencing in the Einstein DNA sequencing facility, all as
previously described (13, 42). Both strands of the cDNA were
sequenced, and sequence changes were confirmed by analysis of an
independent RT-PCR product. The sequence of our laboratory wt virus,
the parent virus used for mutant selection, was found to contain a
lysine (AAA) at position 85 of the capsid protein. This capsid residue
is asparagine (AAC) in the wt infectious clone and published wt virus
sequence (11).
Assays of the mutant phenotype.
The NH4Cl
sensitivity of wt and mutant virus infection was assayed as previously
described by infecting BHK cells in 24-well trays for 90 min with virus
at a multiplicity of ~1 PFU/cell in the presence of the indicated
concentrations of NH4Cl and quantitating virus-specific RNA
synthesis by labeling with [3H]uridine for 3.5 h
(13). Low-pH-dependent conformational changes in the virus
spike proteins were assayed by treating
[35S]methionine-[35S]cysteine-labeled virus
at the indicated pH for 10 min at 37°C in the presence of 1 mM
liposomes prepared by extrusion as indicated. Formation of the E1
homotrimer in these samples was investigated by incubating samples in
sodium dodecyl sulfate (SDS) gel sample buffer for 3 min at 30°C and
analyzing them by SDS-PAGE (24, 45). E1 conversion to
trypsin resistance was assayed by digestion of samples for 10 min at
37°C with 200 µg of tolysulfonyl phenylalanyl chloromethyl ketone
(TPCK)-trypsin per ml in 1% Triton X-100 in phosphate-buffered saline
(PBS) containing calcium and magnesium (24, 35), and the
presence of acid conformation-specific epitopes was determined by
immunoprecipitation with the indicated MAbs (23) followed by
SDS-PAGE analysis. The pH dependence of E1-E2 dimer dissociation was
assayed by coimmunoprecipitation (8, 43). Fluorograms of
SDS-gels were quantitated by PhosphorImager analysis (ImageQuant
version 1.2; Molecular Dynamics, Inc., Sunnyvale, Calif.).
 |
RESULTS |
Functional effects of acid-specific MAbs on virus fusion.
We
wished to compare the functional properties of our three acid
conformation-specific MAbs with those of MAb anti-E1". Previous studies
suggested that the presence of anti-E1" inhibited low-pH-induced fusion
of SFV with cell plasma membranes (45) or liposomes
(44) and low-pH-induced virus-liposome attachment
(44). If the acid conformation-specific MAbs inhibit
virus-cell fusion, this could be the basis of a selection for
MAb-resistant virus mutants. To test for inhibition of SFV-plasma
membrane fusion, virus was bound to BHK cells on ice and treated for 1 min at pH 5.5 to induce fusion, and the infected cells resulting from
virus fusion were quantitated by immunofluorescence with a polyclonal
antibody to the virus spike protein. Under these conditions, no virus
infected the cells during a 1-min treatment at pH 7 and between 209 and 256 cells were infected by virus at pH 5.5 (Table
1). When the pH treatment was performed
in the presence of either MAb anti-E1" or E2-1, a nonneutralizing MAb
to the E2 subunit, little inhibition resulted from the presence of
either MAb at ~300 µg/ml (Table 1, experiment I), from MAb anti-E1"
at higher concentrations (500 or 900 µg/ml) (experiment II), or from
MAb anti-E1" when the conformational changes and fusion were slowed by
incubation at either 20 or 4°C (data not shown). The previous results
reported inhibition of virus-cell membrane fusion by anti-E1" at
concentrations ranging from a 1:10 dilution of ascities fluid to 350 µg of MAb/ml (45). Our acid-specific MAbs E1a-1, E1a-2,
and E1a-3 also had no effect on virus-cell fusion (experiment III). In
contrast, a polyclonal rabbit antibody to the SFV spike specifically
inhibited virus-cell fusion when used under conditions previously shown to neutralize virus infectivity (23) (experiment IV). Thus, the lack of inhibition by the acid conformation-specific MAbs is not
due to an inherent inability to detect inhibition in this assay.
Control ELISA experiments also demonstrated that all four acid-specific
MAbs were fully active in spike protein binding even when maintained at
pH 5.5 (data not shown) and thus were capable of binding the virus
under low-pH conditions.
We examined the ability of the antibodies to inhibit low-pH-induced
virus attachment to liposomes, a step that precedes fusion
(Fig.
1A). After treatment at pH 5.5, about
75% of the added virus
radioactivity cofloated with liposomes,
compared with ~8% after
treatment at pH 7.0 (lanes 1 and 2).
Inclusion of any of the acid
conformation-specific E1 MAbs reduced the
level of binding to
about 45% (lanes 5 to 8). However, similar
inhibition resulted
with a MAb to the E2 subunit, E2-1 (lane 9). The
rabbit polyclonal
anti-spike antibody reduced binding to ~24% of the
added virus
radioactivity (lane 3). Little inhibition resulted from
inclusion
of an unrelated MAb or rabbit antibody (lanes 4 and 10).
Thus,
moderate inhibition of radiolabeled virus binding to liposomes
occurred with either the acid conformation-specific E1 MAbs or
a MAb to
E2, while these MAbs did not appreciably affect productive
virus-cell
fusion. We therefore tested the effects of these MAbs
by using a
sensitive assay for SFV fusion with liposomes.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 1.
Functional effects of MAbs on SFV membrane attachment
and fusion. (A) Virus-liposome attachment.
[35S]methionine-[35S]cysteine-labeled wt
SFV was mixed with liposomes and the indicated antibodies at final
concentrations of 1.2 mM lipid and 50 µg of antibody per ml. The
samples were preequilibrated for 3 to 5 min at 37°C, adjusted to pH
5.5 for 10 min at 37°C unless otherwise indicated, and then returned
to neutral pH. Virus association with liposomes was quantitated by
flotation on sucrose gradients (see Materials and Methods). Data shown
are the average of two experiments. (B) Virus-membrane fusion.
Pyrene-labeled wt SFV (0.6 µM) was mixed with unlabeled liposomes
(200 µM) in the presence of 50 µg of the indicated antibodies per
ml, preequilibrated for 3 to 5 min at 37°C, and adjusted to pH 5.5, and the final extent of fusion was measured after ~30 s at 37°C by
quantitating the decrease in the pyrene eximer peak by
spectrofluorometry (see Materials and Methods). Treatment with the
rabbit preimmune and anti-spike antibodies was performed by overnight
incubation at 4°C followed by incubation as above. Data shown are the
average of two or three experiments.
|
|
We used a recently described fluorescence method based on biosynthetic
labeling of virus with pyrene fatty acid (
3,
44).
Fusion of
pyrene-labeled virus with unlabeled liposomes results
in a reduction in
the pyrene eximer peak, which can be monitored
in a spectrofluorometer
in real time (Fig.
1B). In the absence
of MAbs, approximately 62% of
the input virus fused at pH 5.5
(lane 2) and ~2% fused at pH 7.0 (lane 1). Previous studies reported
an SFV liposome fusion level of
~50% at pH 5.5, which was reduced
to ~20% when 7 to 15 µg of
anti-E1" per ml was included in the
reaction mixture (
44).
In contrast, we found no significant
inhibition of virus-liposome
fusion by MAb anti-E1", E1a-1, or
E2-1 at 50 µg/ml (lanes 5 to 7).
Treatment with the neutralizing
rabbit anti-spike antibody at this
concentration reduced fusion
to 18% (lane 3), while preimmune rabbit
serum was without effect
(lane
4).
Taken together, the data indicate that none of the acid
conformation-specific MAbs to E1, including anti-E1", caused
significant
inhibition of virus fusion with cells or liposomes. Some
inhibition
of radiolabeled virus-liposome attachment resulted, but it
occurred
with a MAb to the E2 subunit as well as with the acid-specific
E1 MAbs. It is not clear why our results differ from those of
previous
studies that reported inhibition, but it is possible
that addition of
solutions of MAbs caused changes in the buffering
capacity of the
fusion reactions, resulting in decreased fusion,
a phenomenon that we
observed with pH treatments close to the
fusion threshold (data not
shown). We adjusted all antibody stock
solutions to the same protein
and buffer concentrations to control
for these effects. As reviewed in
the discussion below, data from
a variety of virus systems has shown
that MAbs can detect relevant
conformational changes during virus
membrane fusion without directly
inhibiting
fusion.
Competition analysis of MAb binding to virus and spike
proteins.
To use the acid conformation-specific MAbs as a tool to
localize the conformational changes in E1, it is important to know if
the MAbs recognize the same site on the SFV E1 polypeptide or identify
several independent E1 sites that become accessible as part of overall
refolding during fusion. All four MAbs are clearly independent
(23), even in one case having been isolated by a different
laboratory (1). However, the properties of the epitope(s)
recognized by these four MAbs are indistinguishable in all of the
assays that have been performed to date. Exposure of the epitope(s) has
similar pH dependence (23), comparable kinetics in in vitro
assays (3, 19) and in vivo during endocytic uptake of virus
by cells (23, 32, 45), and a comparable cholesterol
requirement (23, 26). All four MAbs are also nonneutralizing and do not recognize SDS-denatured E1 (1, 23). We therefore used competition analysis to characterize the locations of the MAb
binding sites on E1. We first established two types of assay systems.
One assay tested the recognition of whole virus particles by the MAbs.
Purified virus was pretreated at acidic or neutral pH, returned to
neutral pH, and tethered to ELISA plates with E2-1, a MAb to the E2
spike subunit. Tethered virus was reacted with biotin-conjugated MAb,
and MAb binding was detected with streptavidin-alkaline phosphatase.
Results for MAb E1a-1 are shown in Fig.
2A. The whole virus ELISA faithfully
reproduced the increased MAb binding observed in previous assays of the
acid-treated virus (23), with binding at nonsaturating MAb
concentrations being five- to sixfold higher in the acid-treated
samples. A second assay tested the reactivity of purified,
detergent-solubilized spike proteins that were adsorbed directly to the
ELISA plate. Similar to results from other low pH-dependent virus
systems (47), direct adsorption of the spike protein caused
sufficient protein unfolding to expose the E1a-1 epitope (Fig. 2B), and
no further increase in MAb binding was observed when the spikes were
pretreated at acidic pH (data not shown). Binding to isolated spike
proteins was somewhat more efficient than binding to intact virus
particles, since a comparable MAb concentration gave similar binding
levels with about a sixfold-lower level of spike proteins in the
isolated preparations. This probably represents steric hindrance in the intact virus, in keeping with the tight packing of the spike proteins. Similar results for both types of assays were obtained with MAb anti-E1" (data not shown).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
MAb E1a-1 binding to whole virus and isolated spike
proteins. (A) Binding to whole virus. Gradient-purified wt SFV was
pretreated at pH 5.5 or 7.0 for 5 min at 37°C as indicated, returned
to neutral pH, and adjusted to 3 µg/ml. Virus was tethered to ELISA
plates that were precoated with a MAb to the E2 spike subunit (E2-1).
Biotin-conjugated MAb E1a-1 was added at the indicated concentrations
and allowed to react with the virus for 1 h at 37°C.
Biotinylated MAb binding was detected by incubation with streptavidin
conjugated to alkaline phosphatase followed by incubation with
substrate, each for 1 h at 37°C. Data shown are a representative
example of four experiments. (B) Binding to adsorbed spike proteins.
Using gradient-purified wt SFV, spike proteins were prepared by Triton
X-114 phase separation and adsorbed directly to ELISA plates at 0.5 µg/ml. Biotin-conjugated MAb E1a-1 was added at the indicated
concentrations and allowed to react with immobilized spike proteins for
1 h at 37°C. MAb binding was detected by incubation with
streptavidan conjugated to alkaline phosphatase followed by incubation
with substrate, each for 1 h at 37°C. The control consists of
biotin-conjugated MAb E1a-1 binding in the absence of adsorbed spike
proteins. Similar low absorbance was observed for binding of an
unrelated MAb to wells containing spike protein. Data shown are a
representative example of two experiments.
|
|
Having established assays for the binding of MAbs to acid-treated virus
and isolated spike proteins, we used these assays
to determine if
various unlabeled MAbs could compete for the binding
of biotin-labeled
E1a-1 or anti-E1" (Fig.
3). The spike
protein
assay showed that all four acid conformation-specific MAbs
competed
for the binding of either MAb E1a-1 (Fig.
3C) or anti-E1"
(Fig.
3D). In both cases, MAb E1a-3 showed the strongest competition.
Negligible competition was observed with non-acid-specific MAbs
against
E1 or E2 (E1-1 and E2-1) or with an unrelated MAb. Competition
analysis
with acid-treated whole virus as the antigen likewise
showed that all
four acid-specific MAbs competed for the binding
of either MAb E1a-1
(Fig.
3A) or MAb anti-E1" (Fig.
3B). When
higher MAb concentrations
were assayed in the whole-virus system,
competition was also observed
when non-acid-specific MAbs against
E1 or E2 were used (Fig.
3A and B).
This is in agreement with
results from others indicating that assembly
of the virus particle
brings epitopes on E1 and E2 into close proximity
(
39). Taken
together, results with the spike protein and
whole-virus ELISAs
demonstrate that all four acid conformation-specific
MAbs bind
to a spatially related site(s) on the SFV E1 subunit.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 3.
Antibody competition analysis. The ELISAs in Fig. 2 were
used to analyze MAb binding to pH 5.5-treated intact wt virus (A and B)
or purified wt spike proteins adsorbed to ELISA plates (C and D). The
binding of biotin-conjugated MAb E1a-1 (A and C) or biotin-conjugated
MAb anti-E1" (B and D) was quantitated at a constant biotin-MAb
concentration of 100 ng/ml, in the presence of the indicated
concentrations of competing, nonconjugated MAbs. Final binding results
(in duplicate) were expressed as a percentage of the reactivity
obtained with biotin-MAb in the absence of any competing MAb.
|
|
Selection and screening for MAb-resistant SFV mutants.
To
specifically localize the binding site(s) for the acid
conformation-specific MAbs, we wished to select for MAb-resistant virus
mutants. The four acid conformation-specific MAbs are nonneutralizing (1, 23), do not inhibit virus-cell fusion (Table 1), and do
not recognize linear sequences, precluding the use of synthetic peptides for mapping studies (1, 23). We therefore used an immunodepletion method to enrich for nonreactive viruses. A
nonmutagenized virus stock was treated briefly at pH 5.5 on ice. The
virus was then incubated with excess biotin-conjugated MAb E1a-1,
antibody-reactive viruses were removed with streptavidin-conjugated
magnetic particles, and the remaining virus was propagated on
independent plates of BHK cells. The conditions of pH treatment were
selected to obtain binding to the MAb (which according to all the
published data represents an irreversible conformational change)
without inactivating infectivity. Under these conditions, only a
10-fold decrease in virus titer resulted from the MAb treatment. The
selection was therefore repeated for a total of nine cycles to increase
the chances of significantly enriching for MAb-resistant mutants. Isolated plaques were then picked from the selected virus stocks, and
the virus was expanded, treated at low pH, and screened by an ELISA for
reactivity with both an E2 MAb and the selecting MAb. Two independent
isolates, SFV 1-8 and SFV 4-2, were chosen for further study on the
basis of their strong reactivity with MAb E2-1 and reduced (SFV 1-8) or
negligible (SFV 4-2) reactivity with MAb E1a-1 after acid treatment.
The SFV 1-8 and SFV 4-2 isolates were propagated on BHK cells at low
multiplicity and yielded titers comparable to those of
wt virus. These
stocks were then diluted, treated for 5 min at
37°C at pH values
ranging from 4.0 to 7.0, and tested in a sensitive
sandwich ELISA for
binding to MAb E1a-1 (Fig.
4). wt SFV
showed
strong binding following treatment at pH 6.0 to 4.0, with an
increase
of ~13-fold in binding of pH 5.0-treated virus compared to
pH
7.0-treated virus. The reduced binding observed in the pH
4.0-treated
sample is probably due to acid inactivation (
3).
The SFV 1-8
isolate showed decreased but significant binding following
treatment
at pH 5.5 to 4.0, while binding by the SFV 4-2 isolate was
not
above background even after treatment at very low pH. Similar
decreases in SFV 1-8 and SFV 4-2 binding to MAb E1a-1 were observed
following pH treatment at 20°C (data not shown), conditions that
favor efficient epitope exposure and decrease acid inactivation
(
3). Irrespective of pH treatment, both SFV 1-8 and SFV 4-2
showed high levels of binding to the anti-E2 MAb E2-1, comparable
to
those of wt virus (data not shown).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 4.
pH dependence of MAb E1a-1 binding to wt and mutant SFV.
wt SFV and the 1-8 and 4-2 mutant virus isolates were diluted to a
final titer of 108 PFU/ml in MES-saline-BSA buffer, and
adjusted to the indicated pH for 5 min at 37°C. The samples were
adjusted to neutral pH and 0.5% Triton X-100 and incubated in ELISA
plates that were precoated with saturating concentrations of MAb E1a-1
(1 µg/ml). Bound spike protein was detected by the addition of a
rabbit polyclonal antibody to the virus spike and an alkaline
phosphatase-conjugated second antibody. Data shown are a representative
example of four experiments.
|
|
The decreased MAb E1a-1 binding observed with SFV 1-8 and SFV 4-2 could
be a direct consequence of amino acid changes in the
MAb binding site
or an indirect effect of a lack of response of
the spike protein to low
pH or of interfering mutations in E1,
E2, or capsid protein. Both
isolates grew efficiently to high
titers, arguing that they must have
functional spike proteins
capable of carrying out virus-membrane fusion
and responding to
acidic pH. The spike protein ELISA described above
(Fig.
2B) was
used to test for steric interference by
non-epitope-related sites.
Epitope exposure in this assay is due to
direct protein adsorption
to the ELISA plate. Unlike the whole-virus
ELISA, no interference
with MAb E1a-1 binding was observed by either E2
or non-acid-specific
E1 MAbs (Fig.
3), suggesting that sites on E1 and
E2 are spatially
separated in the adsorbed spike proteins. Purified
spike proteins
were prepared from wt virus, SFV 1-8, and SFV 4-2; bound
to ELISA
plates at 0.5 µg/ml; and reacted with a series of
biotin-conjugated
MAbs against E1 and E2. As shown in Fig.
5, the SFV 1-8 spike
protein was similar
to wt in binding MAbs to E2 and E1 and in
binding the four acid
conformation-specific MAbs to E1, including
E1a-1. Thus, the decreased
binding of MAb E1a-1 to SFV 1-8 observed
in Fig.
4 is most probably due
to steric interference by amino
acid alterations not in the MAb binding
site. Binding to the SFV
4-2 spike protein was unaltered for the
non-acid-conformation-specific
MAbs E1-1 and E2-1 and for the
single-acid-conformation-specific
MAb anti-E1" (Fig.
5). Strikingly,
however, binding of SFV 4-2
by the three acid conformation-specific
MAbs E1a-1, E1a-2, and
E1a-3 was significantly impaired, ranging from
16% of the wt level
with E1a-1 to 35% with E1a-3. Competition
analysis was then performed
for anti-E1" binding to purified spike
proteins from SFV 1-8 (Fig.
6A) and SFV
4-2 (Fig.
6B). Anti-E1" binding to SFV 1-8 spike proteins
was
efficiently and comparably competed by all four acid
conformation-specific
MAbs, similar to the wt results previously shown
in Fig.
3D. In
contrast, while anti-E1" bound efficiently to spike
proteins from
SFV 4-2, this binding was competed only by anti-E1", not
by any
of the other acid-specific E1 MAbs, even at concentrations of
10 µg/ml. Taken together, these data suggest that the SFV 1-8
E1 protein
has an unaltered MAb E1a-1 binding site while SFV 4-2
E1 carries an
alteration that affects the binding of a subset
of the E1 acid
conformation-specific MAbs including E1a-1.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 5.
MAb binding to isolated mutant spike proteins. wt virus,
SFV 1-8, and SFV 4-2 were purified by gradient sedimentation, and spike
proteins were isolated by Triton X-114 phase separation. Spike proteins
were adsorbed directly to ELISA plates at 0.5 µg/ml and reacted with
100 ng of the indicated biotin-conjugated MAbs per ml. This
concentration was within the linear range of MAb binding to wt spike
proteins (Fig. 2B). MAb binding was detected by reacting with
streptavidin conjugated to alkaline phosphatase, and mutant spike
protein reactivity was expressed as percentage of wt binding. SFV 4-2 binding is shown as solid bars, and SFV 1-8 binding is shown as hatched
bars. Data are a representative example of three experiments.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 6.
Antibody competition analysis of isolated mutant spike
proteins. Purified spike proteins were prepared from SFV 1-8 (A) and
SFV 4-2 (B) and adsorbed to ELISA plates, and the binding of
biotin-conjugated MAb anti-E1" was quantitated in the presence of the
indicated concentrations of competing, nonconjugated MAbs, all as in
Fig. 3D. Final binding results (in duplicate) were expressed as a
percentage of the reactivity obtained with biotin-MAb in the absence of
any competing MAb.
|
|
Biochemical and sequence analysis of SFV mutants.
Given that
our selection involved low-pH treatment of the virus, albeit under
noninactivating conditions, we were concerned that our mutants might be
low-pH resistant. To determine if the spike proteins of both mutants
still mediated entry with a similar pH dependence to that of wt virus,
we tested the sensitivity of virus infection to inhibition by the weak
base NH4Cl (Fig. 7). Cells
were infected with wt, SFV 1-8, SFV 4-2, or the pH shift SFV mutant
fus-1 (13) in the presence of various
concentrations of NH4Cl. Virus infection was quantitated by
monitoring the incorporation of [3H]uridine into viral
RNA (13). As previously observed (13, 25), both
wt and fus-1 infections were inhibited by NH4Cl
and fus-1 was sensitive to lower NH4Cl
concentrations than was wt, in keeping with the relative acid
resistance of the fus-1 fusion (pH threshold of ~pH 5.5 for fus-1 compared to ~pH 6.2 for wt). Both SFV 1-8 and
SFV 4-2 showed NH4Cl sensitivities similar to that of wt
SFV, indicating that both viruses had pH-dependent entry mechanisms
with comparable pH requirements as wt SFV.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 7.
Sensitivity of wt and mutant virus infection to
inhibition by NH4Cl. BHK cells in 24-well trays were
infected with 1 PFU of wt or mutant SFV per cell in the presence of the
indicated concentration of NH4Cl for 90 min. Infection was
then quantitated by determining the incorporation of
[3H]uridine into viral RNA, in the presence of 20 mM
NH4Cl to prevent secondary infection. Data shown are a
representative example of two experiments.
|
|
We examined several of the pH-dependent conformational changes in the
mutant spike proteins. Upon exposure to low pH, the
SFV spike dimer
becomes more labile. Unlike wt SFV, both SFV 1-8
and SFV 4-2 mutants
dissociated in nonionic detergent at pH 8.0
(data not shown),
precluding the usual assays for pH-dependent
dissociation of the dimer.
Similar dimer dissociation in nonionic
detergent was previously
observed for two viruses with mutations
in the E1 fusion peptide
(
8). The formation of the E1 homotrimer
in SFV 1-8 and SFV
4-2 was assayed by using migration on SDS-gels
(
44) and
trypsin resistance (
24). The pH threshold for formation
of
the homotrimer appeared similar in the wt and the two mutants,
although
the efficiency of homotrimerization between pH 6.0 and
5.0 was somewhat
lower in both mutants than in wt virus (data
not shown; see Fig.
8
below). Overall, these data indicate that
both mutants were able to
infect cells and form the E1 homotrimer
in a low-pH-dependent manner.
Thus, the alterations in the antigenicity
of SFV 1-8 and SFV 4-2 do not
appear to cause functional effects
in spike protein fusion
activity.
To establish the amino acid alteration(s) responsible for the antigenic
changes in SFV 4-2 and SFV 1-8, virus RNA was isolated
and amplified by
RT-PCR, and the sequence encoding the structural
proteins was
determined for each virus. The sequence of the SFV
1-8 mutant showed
one amino acid change from that of the wt SFV
parent, histidine to
arginine at position 232 of E2 (H232R, CAT

CGT).
This region from the
wt virus RNA was sequenced and confirmed
the difference between the wt
and SFV 1-8 sequences. No amino
acid changes occurred in the SFV 1-8 E1
protein sequence, in keeping
with the unaltered antigenicity of the
isolated spike protein
(Fig.
5 and
6). The sequence of the SFV 4-2 mutant, surprisingly,
contained the E2 H232R change. In addition, SFV
4-2 contained
a single amino acid change on the E1 subunit, glycine 157 to arginine
(G157R, GGG

AGG). Thus, the E1 G157R mutation appeared to
be the
mutation responsible for the loss of MAb E1a-1 binding in the
SFV 4-2
mutant.
Our model for the effect of these sequence changes on the antigenicity
of E1 was that the E2 H232R mutation in SFV 1-8 affected
the MAb E1a-1
binding site through steric interference (Fig.
4),
which was lost when
the spike protein was isolated and partially
denatured by direct
binding to the ELISA plate (Fig.
5 and
6).
In contrast, although SFV
4-2 contained the same E2 mutation,
the G157R mutation on SFV 4-2 E1
directly prevented MAb E1a-1
binding due to its location in the MAb
binding site. We tested
the role of the E1 G157R mutation by assaying
the immunoreactivity
of isolated homotrimeric E1. Radiolabeled wt, SFV
1-8, and SFV
4-2 virus preparations were mixed with liposomes and
treated at
pH 5.0 to induce the formation of the E1 homotrimer. The
virus
mixtures were adjusted to neutral pH, and aliquots were incubated
with trypsin in 1% Triton X-100 at 37°C, conditions that completely
digest capsid, E2, and monomeric E1 but preserve the trypsin-resistant
E1 homotrimer (
22,
24). The samples were then analyzed by
immunoprecipitation with a rabbit polyclonal anti-spike antibody
which
quantitates the total E1 and E2 (rab), a MAb against E2
(E2-1), and the
acid conformation-specific MAbs E1a-1 and anti-E1".
When treated at pH
5.0, the wt E1 subunit (Fig.
8A) became
immunoreactive
with MAbs E1a-1 and anti-E1" (54 and 69% of the total
E1, respectively).
When the low-pH-treated virus was digested with
trypsin, the capsid
and E2 subunits were degraded, as confirmed by the
absence of
precipitation with MAb E2-1 and loss of capsid protein (not
shown
on this gel), while the E1 subunit was resistant to trypsin (44%
of the total E1). Immunoprecipitation analysis showed that 88
to 100%
of the trypsin-resistant wt E1 was recognized by MAbs
E1a-1 and
anti-E1", respectively. Thus, trypsin digestion removed
monomeric,
non-acid-reactive E1, leaving almost exclusively the
homotrimeric,
acid-reacted conformation of E1, which was efficiently
precipitated
with both acid conformation-specific MAbs. Similar
results were
observed with low-pH-treated E1 from SFV 1-8 (Fig.
8B), which was
recognized by MAbs E1a-1 and anti-E1" at 31 and
46% of the total E1,
respectively, and became trypsin resistant
(29% of the total E1).
Similar to wt E1, the trypsin-resistant
E1 from SFV 1-8 was completely
precipitated by either MAb E1a-1
or anti-E1" (116 and 102%,
respectively). In contrast, low-pH-treated
E1 from the SFV 4-2 mutant
(Fig.
8C) became trypsin resistant
(31% of the total E1) and was
recognized by anti-E1" (29% of the
total E1) but was not efficiently
precipitated by MAb E1a-1 (1%
of the total E1). Even when E2, capsid,
and monomeric E1 were
removed by trypsin digestion, the remaining
homotrimeric E1, although
recognized by anti-E1" (59% of the
trypsin-resistant E1), was
not recognized by MAb E1a-1 (9% of the
trypsin-resistant E1).
Thus, in the absence of the E2 protein, the
G157R mutation on
SFV 4-2 E1 strongly interfered with the binding of
MAb E1a-1 and
to a small extent with that of anti-E1".

View larger version (72K):
[in this window]
[in a new window]
|
FIG. 8.
MAb reactivity of isolated E1 homotrimers from wt and
mutant SFV.
[35S]methionine-[35S]cysteine-labeled wt
SFV (A), SFV 1-8 (B), or SFV 4-2 (C) was mixed with liposomes (final
concentration, 0.8 mM), adjusted to the indicated pH for 10 min at
37°C, and returned to neutral pH. One set of samples (pH 5 plus
trypsin) was then treated with 200 µg of trypsin per ml in 1% Triton
X-100 in PBS for 10 min at 37°C to digest E2, capsid, and any
nontrimerized E1, and the digestion was terminated by the addition of
trypsin inhibitor. All other samples were treated with premixed trypsin
and trypsin inhibitor in 1% Triton X-100 in PBS. Antibody reactivity
was analyzed by immunoprecipitation with the indicated antibodies
followed by SDS-PAGE. rab indicates a rabbit polyclonal antibody
against the SFV E1 and E2 subunits.
|
|
Comparison of alphavirus sequences in the E1 G157 region showed that
this is a quite unconserved area of E1 that contains
numerous charged
amino acids. Position 157 is a glycine residue
in SFV, in the closely
related Ross River virus, and in eastern
equine encephalitis virus. In
many other alphaviruses, the E1
157 position contains a charged amino
acid, and for western equine
encephalitis virus, like SFV 4-2, this
residue is arginine. Thus,
it is reasonable that the introduction into
SFV of the large,
basic arginine side chain in place of the glycine
hydrogen would
act to disrupt the binding site for three acid
conformation-specific
MAbs but not have deleterious effects on the
overall structure
and function of
E1.
 |
DISCUSSION |
Functional effects of the acid-specific MAbs.
Our studies
showed that the four acid conformation-specific E1 MAbs do not have
strong inhibitory effects on SFV-membrane fusion. SFV fusion is
extremely rapid and is completed within seconds at 37°C
(3). Cryoelectron microscopy studies have shown that spike
protein conformational changes can be detected within the first 25 ms
of low-pH treatment (10). The lack of effect of the MAbs on
fusion thus may be due either to the rapid completion of fusion prior
to recognition by MAb or to noninhibitory MAb binding prior to fusion.
Our data do not differentiate between these two possibilities, but
decreasing the rate of virus fusion with the cell plasma membrane by
low pH incubation at either 20 or 4°C did not increase inhibition by
added MAbs (see results above).
Results from several virus systems indicate that MAbs to spike protein
epitopes involved in fusion exhibit a wide variety
of properties in
virus infection and fusion assays. For example,
studies with the
flavivirus West Nile virus have characterized
a polyclonal antibody
that inhibits virus-liposome fusion, although
it is not clear if this
antibody acts by steric interference,
masking of the hydrophobic virus
fusion peptide, or stabilizing
the neutral-pH form of the spike protein
(
16). Acid conformation-specific
MAbs to the influenza virus
hemagglutinin (HA) have been informative
and extensively used reagents
to map regions of HA that become
exposed during its fusogenic
conformational changes (
46-48). Some
MAbs to HA block virus
fusion within endosomes (
18). An antibody
to the
membrane-proximal region of HA is nonneutralizing and does
not
recognize the low-pH conformation of HA. However, this MAb
appears to
inhibit both the low-pH-dependent conformational changes
in HA and
virus-induced cell-cell fusion (
41). In contrast,
and
similar to our results with the SFV MAbs, several widely used
acid
conformation-specific MAbs to HA are nonneutralizing at either
acidic
or neutral pH and do not inhibit virus fusion (
46).
It is clear that MAbs that recognize low pH-treated SFV spike proteins
also can have a variety of properties (
1,
23).
The kinetics,
pH dependence, cholesterol and sphingolipid dependence,
and extensively
characterized in vitro and in vivo properties
of the acid
conformation-specific epitope studied here argue strongly
for its
relevance to the infectious fusion reaction of SFV. Thus,
the mapping
of this epitope provides information on a biologically
important spike
protein conformational
change.
Evidence for mapping of the E1a-1 epitope.
Competition studies
on isolated wt spike proteins demonstrated that all four independent
acid conformation-specific MAbs bound to sites on E1 that were either
identical or sufficiently adjacent to produce binding interference. The
SFV 4-2 mutation, E1 G157R, decreased the binding of the acid
conformation-specific MAbs E1a-1, E1a-2, and E1a-3, while the binding
of anti-E1" was essentially unaffected. Thus, while the competition
data suggested close proximity of the anti-E1" binding site to those of
the other acid conformation-specific MAbs, the SFV 4-2 mutation
indicated that these epitopes were nevertheless distinct. It was
possible that the SFV 4-2 mutation was acting indirectly to inhibit MAb
binding by inducing a conformational change in a distant E1 epitope
(31). We have tested the reactivity of E1 after triggering
epitope exposure by acid treatment of virus particles and assay of the
spike protein dimer (Fig. 4), by direct adsorption and denaturation of
purified spike proteins on ELISA plates (Fig. 5 and 6), and by acid
treatment of virus followed by isolation of homotrimeric E1 (Fig. 8).
The decreased binding to SFV 4-2 E1 under all assay conditions strongly
suggests that the 4-2 mutation acts by directly affecting the MAb
binding site and therefore that the G157 region of E1 is masked in the
neutral-pH structure and becomes accessible during fusion-permissive conditions.
In addition to the unique E1 G157D mutation, SFV 4-2 shares an
additional mutation, E2 H232R, with the SFV 1-8 isolate. Since
SFV 4-2 and SFV 1-8 were independently derived, the presence of
this mutation
in both isolates may suggest that a virus containing
the shared
mutation was present at nondetectable levels in the
original
plaque-purified parental virus stock. Alternatively,
the mutation may
have arisen spontaneously at a high frequency
during selection and been
rescued by its conferred effects on
MAb recognition. The E2 H232R
mutation does not have strong effects
on the activity or pH dependence
of the mutant fusion proteins
(Fig.
7) but does cause the 1-8 mutant
spike protein to be less
well recognized by MAb E1a-1 when it is
assayed under conditions
that preserve the spike protein dimer (Fig.
4). In contrast, when
assayed by direct binding to ELISA plates or as
an isolated E1
homotrimer, the 1-8 mutant showed comparable MAb binding
to that
of wt SFV (Fig.
5,
6, and
8). The finding that MAb reactivity
is decreased only when the intact SFV 1-8 spike dimer is assayed
suggests that the E2 H232R mutation directly interferes with the
accessibility of the MAb E1a-1 epitope. Alternatively, the H232R
mutation could be acting indirectly to cause another site on E2
to mask
the E1
epitope.
Comparisons with other alphavirus epitopes.
Anti-E1" was
originally designated UM8.64 and characterized as nonneutralizing and
nonprotective in mice but active in hemagglutination inhibition
(1). This MAb defined an antigenic determinant termed E1d in competition analysis. Our competition analysis also
places MAbs E1a-1, E1a-2, and E1a-3 in the E1d group with
anti-E1". Thus, to date, all the acid conformation-specific MAbs
against SFV E1 fall into this group, and it is not known if additional,
noncompeting acid-specific antigenic determinants exist. However,
although the competition analysis shows that all four acid
conformation-specific MAbs have spatially related binding sites, the
SFV 4-2 mutant data indicate that three of the current members of the
E1d group bind an epitope different from that of anti-E1".
The exact recognition site of anti-E1" has not been defined, except for
its spatial relationship to G157 in competition analysis.
It is of interest to compare the G157 epitope to epitopes that were
previously defined in the Sindbis virus E1 protein. Sindbis
virus is
another well-characterized member of the alphaviruses
(
40)
that has been shown to enter cells by a membrane fusion
reaction that
is dependent on low pH (
14) and cholesterol (
27).
Sindbis virus was selected for resistance to a neutralizing MAb
that
recognizes an E1 site accessible on the surface of native
virus
(
34,
37). Interestingly, virus mutants resistant to
this MAb
had mutations of E1 glycine 132 to either arginine or
glutamic acid
(
39). Thus, although this epitope is unrelated
to the acid
conformation-specific epitope described here, it provides
another
example of an E1 G

R mutation that blocks MAb binding,
similar to the
G157R mutation of the SFV 4-2
mutant.
Sindbis virus also has interesting E1 and E2 sites termed transitional
epitopes, which are unmasked during virus penetration
into the cell
(
9). Similar to the epitopes we have characterized
here in
SFV, the Sindbis E1 transitional epitopes are shielded
and
nonneutralizing in native Sindbis virus and can be exposed
by treatment
of virus particles with low pH, heat, or reducing
agents or by direct
adsorption to ELISA plates (
29). However,
unlike the acid
conformation-specific SFV epitopes described here
(
23,
32),
the in vivo exposure of the Sindbis virus transitional
epitopes occurs
following virus-receptor binding at the cell surface
and is not blocked
by agents that block endosomal acidification
(
9). Sindbis
virus mutants were isolated based on their resistance
to two E1 MAbs
recognizing independent transitional epitopes.
The mutations that
confer resistance map to E1 residue 300 for
one epitope and to E1
residue 361 or 381 for a second epitope
(
30). Both the
locations and properties of these transitional
epitopes thus appear
distinct from the acid conformation-specific
epitope mapped here. It is
not known if the Sindbis E1 transitional
epitopes become accessible
following detergent solubilization
of virus, which would suggest a
possible analogy to several SFV
E1 MAbs that recognize sites which are
shielded in the intact
virus particle (
23).
Conclusions.
The data presented here suggest that a region of
E1 defined by the G157R mutation becomes exposed or more accessible
during the low-pH-induced fusion of SFV and can then be recognized by the acid conformation-specific MAbs E1a-1, E1a-2, and E1a-3. The acid-dependent refolding involving the E1 157 region is part of the
overall series of conformational changes in the SFV spike protein
during fusion. Kinetic studies of fusion (3) and results with SFV mutants with altered E1-E2 dimer dissociation (13, 33) indicate that acid conformation-specific epitope exposure is
blocked until the E1-E2 dimer dissociates. Results with an SFV fusion
peptide mutant indicate that the acid conformation-specific MAbs
recognize a conformational change that can occur in the absence of E1
trimerization (24). Taken together, the results to date suggest a fusion model in which G157 epitope exposure occurs after E1-E2 dimer dissociation but prior to formation of the E1 homotrimer and insertion of the SFV fusion peptide into the target membrane. The
kinetics of exposure of the G157 epitope are strongly enhanced by the
presence of cholesterol and sphingolipid-containing liposomes (4,
6, 26), suggesting that E1 interacts in some way with the target
membrane already during this relatively early stage of the fusion
reaction. Future studies will address the role of lipid in the
conformational changes that lead to epitope exposure. In addition,
advances in cryoelectron microscopy (5, 10) may make it
possible to localize the G157 region in the virus particle during
exposure to low pH. As our knowledge of the SFV spike protein structure
becomes more detailed, it may be possible to design virus mutations
that could inhibit the rearrangement of the G157 region
(15), thus potentially trapping an intermediate in
virus-membrane fusion and permitting detailed characterization of its phenotype.
 |
ACKNOWLEDGMENTS |
We thank Matthew Scharff, Philippe Valadon, Susan Buhl, and other
members of the Scharff laboratory and the Einstein hybridoma facility
for their very generous help and insightful advice during this work. We
thank Jan Wilschut and Yolande Smit for very helpful advice and
protocols for the preparation and use of pyrene-labeled SFV, and we
thank Harm Snippe for MAb anti-E1". We also thank the members of our
laboratory for helpful discussions and suggestions and Duncan Wilson
and the members of our laboratory for critical reading of the manuscript.
This work was supported by a grant to M.K. from the Public Health
Service (GM52929), by the Jack K. and Helen B. Lazar Fellowship in Cell
Biology, and by Cancer Center Core Support Grant NIH/NCI P30-CA13330.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Cell Biology, Albert Einstein College of Medicine, 1300 Morris Park
Ave., Bronx, NY 10461. Phone: (718) 430-3638. Fax: (718) 430-8574. E-mail address: kielian{at}aecom.yu.edu.
 |
REFERENCES |
| 1.
|
Boere, W. A. M.,
T. Harmsen,
J. Vinje,
B. J. Benaissa-Trouw,
C. A. Kraaijeveld, and H. Snippe.
1984.
Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities.
J. Virol.
52:575-582[Abstract/Free Full Text].
|
| 2.
|
Bordier, C.
1981.
Phase separation of integral membrane proteins in Triton X-114 solution.
J. Biol. Chem.
256:1604-1607[Abstract/Free Full Text].
|
| 3.
|
Bron, R.,
J. M. Wahlberg,
H. Garoff, and J. Wilschut.
1993.
Membrane fusion of Semliki Forest virus in a model system: correlation between fusion kinetics and structural changes in the envelope glycoprotein.
EMBO J.
12:693-701[Medline].
|
| 4.
| Chatterjee, P. K., M. Vashishtha, and M. Kielian. Submitted for publication.
|
| 5.
|
Cheng, R. H.,
R. J. Kuhn,
N. H. Olson,
M. G. Rossman,
H.-K. Choi,
T. J. Smith, and T. S. Baker.
1995.
Nucleocapsid and glycoprotein organization in an enveloped virus.
Cell
80:621-630[Medline].
|
| 6.
|
Corver, J.
1998.
Membrane fusion activity of Semliki Forest virus. Ph.D. thesis.
University of Groningen, Groningen, The Netherlands
|
| 7.
|
Corver, J.,
R. Bron,
H. Snippe,
C. Kraaijeveld, and J. Wilschut.
1997.
Membrane fusion activity of Semliki forest virus in a liposomal model system: specific inhibition by Zn2+ ions.
Virology
238:14-21[Medline].
|
| 8.
|
Duffus, W. A.,
P. Levy-Mintz,
M. R. Klimjack, and M. Kielian.
1995.
Mutations in the putative fusion peptide of Semliki Forest virus affect spike protein oligomerization and virus assembly.
J. Virol.
69:2471-2479[Abstract].
|
| 9.
|
Flynn, D. C.,
W. J. Meyer,
J. M. Mackenzie, and R. E. Johnston.
1990.
A conformational change in Sindbis virus glycoproteins E1 and E2 is detected at the plasma membrane as a consequence of early virus-cell interaction.
J. Virol.
64:3643-3653[Abstract/Free Full Text].
|
| 10.
|
Fuller, S. D.,
J. A. Berriman,
S. J. Butcher, and B. E. Gowen.
1995.
Low pH induces swiveling of the glycoprotein heterodimers in the Semliki Forest virus spike complex.
Cell
81:715-725[Medline].
|
| 11.
|
Garoff, H.,
A.-M. Frischauf,
K. Simons,
H. Lehrach, and H. Delius.
1980.
The capsid protein of Semliki Forest virus has clusters of basic amino acids and prolines in its amino-terminal region.
Proc. Natl. Acad. Sci. USA
77:6376-6380[Abstract/Free Full Text].
|
| 12.
|
Garoff, H.,
A.-M. Frischauf,
K. Simons,
H. Lehrach, and H. Delius.
1980.
Nucleotide sequence of cDNA coding for Semliki Forest virus membrane glycoproteins.
Nature
288:236-241[Medline].
|
| 13.
|
Glomb-Reinmund, S., and M. Kielian.
1998.
fus-1, a pH-shift mutant of Semliki Forest virus, acts by altering spike subunit interactions via a mutation in the E2 subunit.
J. Virol.
72:4281-4287[Abstract/Free Full Text].
|
| 14.
|
Glomb-Reinmund, S., and M. Kielian.
1998.
The role of low pH and disulfide shuffling in the entry and fusion of Semliki Forest virus and Sindbis virus.
Virology
248:372-381[Medline].
|
| 15.
|
Godley, L.,
J. Pfeifer,
D. Steinhauer,
B. Ely,
G. Shaw,
R. Kaufmann,
E. Suchanek,
C. Pabo,
J. J. Skehel,
D. C. Wiley, and S. Wharton.
1992.
Introduction of intersubunit disulfide bonds in the membrane-distal region of the influenza hemagglutinin abolishes membrane fusion activity.
Cell
68:635-645[Medline].
|
| 16.
|
Gollins, S. W., and J. S. Porterfield.
1986.
A new mechanism for the neutralization of enveloped viruses by antiviral antibody.
Nature
321:244-246[Medline].
|
| 17.
|
Hughson, F. M.
1995.
Structural characterization of viral fusion proteins.
Curr. Biol.
5:265-274[Medline].
|
| 18.
|
Imai, M.,
K. Sugimoto,
K. Okazaki, and H. Kida.
1998.
Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin.
Virus Res.
53:129-139[Medline].
|
| 19.
|
Justman, J.,
M. R. Klimjack, and M. Kielian.
1993.
Role of spike protein conformational changes in fusion of Semliki Forest virus.
J. Virol.
67:7597-7607[Abstract/Free Full Text].
|
| 20.
|
Kielian, M.
1995.
Membrane fusion and the alphavirus life cycle.
Adv. Virus Res.
45:113-151[Medline].
|
| 21.
| Kielian, M., P. K. Chatterjee, D. L. Gibbons,
and Y. E. Lu. Specific role for lipids in virus fusion and
exit: Examples from the alphaviruses. Subcell. Biochem., in press.
|
| 22.
|
Kielian, M., and A. Helenius.
1985.
pH-induced alterations in the fusogenic spike protein of Semliki Forest virus.
J. Cell Biol.
101:2284-2291[Abstract/Free Full Text].
|
| 23.
|
Kielian, M.,
S. Jungerwirth,
K. U. Sayad, and S. DeCandido.
1990.
Biosynthesis, maturation, and acid-activation of the Semliki Forest virus fusion protein.
J. Virol.
64:4614-4624[Abstract/Free Full Text].
|
| 24.
|
Kielian, M.,
M. R. Klimjack,
S. Ghosh, and W. A. Duffus.
1996.
Mechanisms of mutations inhibiting fusion and infection by Semliki Forest virus.
J. Cell Biol.
134:863-872[Abstract/Free Full Text].
|
| 25.
|
Kielian, M. C.,
S. Keränen,
L. Kääriäinen, and A. Helenius.
1984.
Membrane fusion mutants of Semliki Forest virus.
J. Cell Biol.
98:139-145[Abstract/Free Full Text].
|
| 26.
|
Klimjack, M. R.,
S. Jeffrey, and M. Kielian.
1994.
Membrane and protein interactions of a soluble form of the Semliki Forest virus fusion protein.
J. Virol.
68:6940-6946[Abstract/Free Full Text].
|
| 27.
|
Lu, Y. E.,
T. Cassese, and M. Kielian.
1999.
The cholesterol requirement for Sindbis virus entry and exit and characterization of a spike protein region involved in cholesterol dependence.
J. Virol.
73:4272-4278[Abstract/Free Full Text].
|
| 28.
|
Martys, J. L.,
C. Wjasow,
D. M. Gangi,
M. C. Kielian,
T. E. McGraw, and J. M. Backer.
1996.
Wortmannin-sensitive trafficking pathways in Chinese hamster ovary cells differential effects on endocytosis and lysosomal sorting.
J. Biol. Chem.
271:10953-10962[Abstract/Free Full Text].
|
| 29.
|
Meyer, W. J.,
S. Gidwitz,
V. K. Ayers,
R. J. Schoepp, and R. E. Johnston.
1992.
Conformational alteration of Sindbis virion glycoproteins induced by heat, reducing agents, or low pH.
J. Virol.
66:3504-3513[Abstract/Free Full Text].
|
| 30.
|
Meyer, W. J., and R. E. Johnston.
1993.
Structural rearrangement of infecting Sindbis virions at the cell surface: mapping of newly accessible epitopes.
J. Virol.
67:5117-5125[Abstract/Free Full Text].
|
| 31.
|
Parry, N.,
G. Fox,
D. Rowlands,
F. Brown,
E. Fry,
R. Acharya,
D. Logan, and D. Stuart.
1990.
Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus.
Nature
347:569-572[Medline].
|
| 32.
|
Phalen, T., and M. Kielian.
1991.
Cholesterol is required for infection by Semliki Forest virus.
J. Cell Biol.
112:615-623[Abstract/Free Full Text].
|
| 33.
|
Salminen, A.,
J. M. Wahlberg,
M. Lobigs,
P. Liljeström, and H. Garoff.
1992.
Membrane fusion process of Semliki Forest virus. II. Cleavage-dependent reorganization of the spike protein complex controls virus entry.
J. Cell Biol.
116:349-357[Abstract/Free Full Text].
|
| 34.
|
Schmaljohn, A. L.,
K. M. Kokubun, and G. A. Cole.
1983.
Protective monoclonal antibodies define maturational and pH-dependent antigenic changes in Sindbis virus E1 glycoprotein.
Virology
130:144-154[Medline].
|
| 35.
|
Schmid, S. L.,
R. Fuchs,
M. Kielian,
A. Helenius, and I. Mellman.
1989.
Acidification of endosome subpopulations in wild-type Chinese hamster ovary cells and temperature-sensitive acidification-defective mutants.
J. Cell Biol.
108:1291-1300[Abstract/Free Full Text].
|
| 36.
|
Skehel, J. J., and D. C. Wiley.
1998.
Coiled coils in both intracellular vesicle and viral membrane fusion.
Cell
95:871-874[Medline].
|
| 37.
|
Stec, D. S.,
A. Waddell,
C. S. Schmaljohn,
B. A. Cole, and A. L. Schmaljohn.
1986.
Antibody-selected variation and reversion in Sindbis virus neutralization epitopes.
J. Virol.
57:715-720[Abstract/Free Full Text].
|
| 38.
|
Stockert, R. J.,
B. Potvin,
L. Tao,
P. Stanley, and A. W. Wolkoff.
1995.
Human hepatoma cell mutant defective in cell surface protein trafficking.
J. Biol. Chem.
270:16107-16113[Abstract/Free Full Text].
|
| 39.
|
Strauss, E. G.,
D. S. Stec,
A. L. Schmaljohn, and J. H. Strauss.
1991.
Identification of antigenically important domains in the glycoproteins of Sindbis virus by analysis of antibody escape variants.
J. Virol.
65:4654-4664[Abstract/Free Full Text].
|
| 40.
|
Strauss, J. H., and E. G. Strauss.
1994.
The alphaviruses: gene expression, replication, and evolution.
Microbiol. Rev.
58:491-562[Abstract/Free Full Text].
|
| 41.
|
Vanlandschoot, P.,
E. Beirnaert,
B. Barrere,
B. Millar,
S. Wharton,
W. M. Jou, and W. Fiers.
1998.
An antibody which binds to the membrane-proximal end of influenza virus haemagglutinin (H3 subtype) inhibits the low-pH-induced conformational changes and cell-cell fusion but does not neutralize virus.
J. Gen. Virol.
79:1781-1791[Abstract].
|
| 42.
|
Vashishtha, M.,
T. Phalen,
M. T. Marquardt,
J. S. Ryu,
A. C. Ng, and M. Kielian.
1998.
A single point mutation controls the cholesterol dependence of Semliki Forest virus entry and exit.
J. Cell Biol.
140:91-99[Abstract/Free Full Text].
|
| 43.
|
Wahlberg, J. M.,
W. A. M. Boere, and H. Garoff.
1989.
The heterodimeric association between the membrane proteins of Semliki Forest virus changes its sensitivity to low pH during virus maturation.
J. Virol.
63:4991-4997[Abstract/Free Full Text].
|
| 44.
|
Wahlberg, J. M.,
R. Bron,
J. Wilschut, and H. Garoff.
1992.
Membrane fusion of Semliki Forest virus involves homotrimers of the fusion protein.
J. Virol.
66:7309-7318[Abstract/Free Full Text].
|
| 45.
|
Wahlberg, J. M., and H. Garoff.
1992.
Membrane fusion process of Semliki Forest virus. I. Low pH-induced rearrangement in spike protein quaternary structure precedes virus penetration into cells.
J. Cell Biol.
116:339-348[Abstract/Free Full Text].
|
| 46.
|
Webster, R. G.,
L. E. Brown, and D. C. Jackson.
1983.
Changes in the antigenicity of the hemagglutinin molecule of H3 influenza virus at acidic pH.
Virology
126:587-599[Medline].
|
| 47.
|
White, J. M., and I. A. Wilson.
1987.
Anti-peptide antibodies detect steps in a protein conformational change: low-pH activation of the influenza hemagglutinin.
J. Cell Biol.
105:2887-2896[Abstract/Free Full Text].
|
| 48.
|
Wiley, D. C., and J. J. Skehel.
1987.
The structure and function of the hemagglutinin membrane glycoprotein of influenza virus.
Annu. Rev. Biochem.
56:365-394[Medline].
|
| 49.
|
Wilschut, J.,
J. Corver,
J. L. Nieva,
R. Bron,
L. Moesby,
K. C. Reddy, and R. Bittman.
1995.
Fusion of Semliki Forest virus with cholesterol-containing liposomes at low pH: a specific requirement for sphingolipids.
Mol. Membr. Biol.
12:143-149[Medline].
|
Journal of Virology, December 1999, p. 10029-10039, Vol. 73, No. 12
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Liao, M., Kielian, M.
(2006). Site-Directed Antibodies against the Stem Region Reveal Low pH-Induced Conformational Changes of the Semliki Forest Virus Fusion Protein. J. Virol.
80: 9599-9607
[Abstract]
[Full Text]
-
Liao, M., Kielian, M.
(2005). Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. JCB
171: 111-120
[Abstract]
[Full Text]
-
Chanel-Vos, C., Kielian, M.
(2004). A Conserved Histidine in the ij Loop of the Semliki Forest Virus E1 Protein Plays an Important Role in Membrane Fusion. J. Virol.
78: 13543-13552
[Abstract]
[Full Text]
-
Gibbons, D. L., Ahn, A., Liao, M., Hammar, L., Cheng, R. H., Kielian, M.
(2004). Multistep Regulation of Membrane Insertion of the Fusion Peptide of Semliki Forest Virus. J. Virol.
78: 3312-3318
[Abstract]
[Full Text]
-
Hammar, L., Markarian, S., Haag, L., Lankinen, H., Salmi, A., Cheng, R. H.
(2003). Prefusion Rearrangements Resulting in Fusion Peptide Exposure in Semliki Forest Virus. J. Biol. Chem.
278: 7189-7198
[Abstract]
[Full Text]
-
Zhang, W., Mukhopadhyay, S., Pletnev, S. V., Baker, T. S., Kuhn, R. J., Rossmann, M. G.
(2002). Placement of the Structural Proteins in Sindbis Virus. J. Virol.
76: 11645-11658
[Abstract]
[Full Text]
-
Ahn, A., Gibbons, D. L., Kielian, M.
(2002). The Fusion Peptide of Semliki Forest Virus Associates with Sterol-Rich Membrane Domains. J. Virol.
76: 3267-3275
[Abstract]
[Full Text]
-
Lu, Y. E., Eng, C. H., Shome, S. G., Kielian, M.
(2001). In Vivo Generation and Characterization of a Soluble Form of the Semliki Forest Virus Fusion Protein. J. Virol.
75: 8329-8339
[Abstract]
[Full Text]
-
Gibbons, D. L., Ahn, A., Chatterjee, P. K., Kielian, M.
(2000). Formation and Characterization of the Trimeric Form of the Fusion Protein of Semliki Forest Virus. J. Virol.
74: 7772-7780
[Abstract]
[Full Text]
-
Phinney, B. S., Blackburn, K., Brown, D. T.
(2000). The Surface Conformation of Sindbis Virus Glycoproteins E1 and E2 at Neutral and Low pH, as Determined by Mass Spectrometry-Based Mapping. J. Virol.
74: 5667-5678
[Abstract]
[Full Text]
-
Chatterjee, P. K., Vashishtha, M., Kielian, M.
(2000). Biochemical Consequences of a Mutation That Controls the Cholesterol Dependence of Semliki Forest Virus Fusion. J. Virol.
74: 1623-1631
[Abstract]
[Full Text]